key: cord-0707541-stg2bga7 authors: Patrick, Casey; Crowe, Remle P.; Ward, Brad; Mohammed, Ali; Keene, Kelley Rogers; Dickson, Robert title: Feasibility of prehospital esmolol for refractory ventricular fibrillation date: 2022-04-09 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12700 sha: ad7c8bf09a2ffc4c0e1e3301ebf83c697c71da5e doc_id: 707541 cord_uid: stg2bga7 BACKGROUND: Esmolol may increase survival for patients with refractory ventricular fibrillation (RVF); however, information related to esmolol use in the prehospital environment is limited. We aimed to assess the feasibility of prehospital bolus dose esmolol for patients with RVF treated by a high‐volume, ground‐based emergency medical services (EMS) agency. METHODS: Esmolol (0.5 mg/kg single bolus) was added to the RVF protocol on December 10, 2018. Feasibility was defined as esmolol administration in >75% of RVF cases. Secondarily, we compared the proportion of patients with prehospital return of spontaneous circulation (ROSC), 24‐hour survival, and survival to hospital discharge during the intervention period (December 10, 2018–June 10, 2020) to a historical control period (June 10, 2017–December 9, 2018) using chi‐square tests. RESULTS: Before the protocol change, 63 patients with RVF were identified. After esmolol was added, 70 patients with RVF were identified and 61 (87%) received esmolol. Prehospital ROSC was higher in the esmolol group compared to the historical control group, though statistical significance was not reached (38% versus 24%, P = 0.09). Overall, few patients survived to 24 hours (esmolol n = 15, pre‐esmolol n = 16) and fewer survived to hospital discharge (esmolol n = 5, pre‐esmolol n = 5), precluding stable statistical comparisons. CONCLUSION: Collectively, these findings suggest that EMS clinicians are able to accurately identify RVF and administer esmolol in the prehospital setting and that ROSC may be increased. Further large‐scale studies are needed to determine the effect of prehospital esmolol for RVF as it relates to neurologically intact hospital discharge. Refractory ventricular fibrillation (RVF) is characterized as cardiac arrest with persistent ventricular fibrillation despite initiation of American Heart Association advanced cardiac life support (ACLS), three defibrillations, three 1 mg doses of epinephrine and amiodarone administration. 1,2 RVF represents a specific subset of out-of-hospital cardiac arrest (OHCA) unlike the classic electrical storm described in the cardiology literature. 3, 4 Outcomes for patients experiencing RVF are dismal, even when current standards of care are delivered. 5,6 RVF is thought to result from adrenergic surge, often secondary to acute coronary occlusion and myocardial ischemia. Esmolol, an ultrashort acting beta-adrenergic antagonist, has been proposed as a treatment option for patients with RVF. 7 Two small hospital-based observational studies collectively totaling 66 patients 8, 9 and earlier animal studies [10] [11] [12] have suggested increased survival in RVF with the addition of esmolol to standard ACLS care. However, RVF is often first encountered outside the emergency department or hospital environment, warranting examination of esmolol as a potential treatment option for use by emergency medical services (EMS) clinicians in the prehospital setting. In this study, we sought to evaluate the feasibility of prehospital bolus dose esmolol for patients with cardiac arrest progressing to RVF within a high-volume, ground-based EMS agency. Secondarily, we compared prehospital return of spontaneous circulation (ROSC), 24-hour survival, and survival to hospital discharge between patients treated with esmolol and those treated during a historical control period immediately preceding the introduction of esmolol into the prehospital RVF protocol. In this retrospective observational analysis, we examined the effects of introducing esmolol to the cardiac arrest with RVF protocol of a large, suburban, EMS agency in Texas. Montgomery County Hospital District (MCHD) is a ground-based EMS agency that employs approximately 250 advanced life support medics and provides medical direction for more than 1000 first responders. In a service area encompassing 1100 square miles, MCHD responds to more than 70,000 annual calls for service. This study was approved by the institutional review board at This before-and-after study evaluated an emergency medical services (EMS) protocol change for refractory ventricular fibrillation that added a bolus of intravenous esmolol. The authors found that the EMS system was able to successfully implement the protocol change. The results also suggested that patients treated with esmolol may have higher rates of return of spontaneous circulation, though this was not statistically significant and is a hypothesis to be tested in future studies. The Baylor College of Medicine and a waiver of informed consent was granted. The prehospital electronic patient care record (ePCR) system was queried for all 9-1-1 encounters with cardiac arrest and 3 or more defibrillations by EMS. EMS patient care records were then individually and independently reviewed by 2 physician authors (C.P. and R.D.) to determine presence of true RVF as defined by shock resistance with persistent ventricular fibrillation, and no degeneration into pulseless electrical activity or asystole, during the initial ACLS treatment phase. Cardiac arrests with traumatic etiologies were excluded from this analysis as traumatic cardiac arrest has a lower incidence, substantially lower rates of survival, and distinct definitive interventions compared to cardiac arrest with medical etiologies. Data elements were abstracted directly from the prehospital ePCR and hospital electronic medical records by a 2-person expert review panel consisting of 1 physician (CP) and 1 paramedic (BW) using a standardized data collection form including patient demographic information, prehospital medications, prehospital interventions, and hospital disposition. We defined feasibility based on criteria often used as acceptability thresholds for pragmatic pilot studies. 13 We evaluated the effects of adding esmolol to the prehospital protocol During the control period before the addition of esmolol to the out- After esmolol administration 38% (n = 23) of patients achieved prehospital ROSC compared to 24% (n = 15) of patients from the control period, though this difference did not reach statistical significance (P = 0.09). Survival at 24 hours was similar for those who received esmolol (25%, n = 15) and those from the control period (25%, n = 16). In total, 5 patients (8%) from the esmolol group and 5 patients (8%) from the control group survived to hospital discharge ( Table 2 ). After adjusting for patient age, sex, and initial rhythm, there was a 2-fold increase in odds of ROSC during the EMS encounter (odds ratio: In summary, this evaluation demonstrated feasibility of esmolol use for RVF within a ground-based EMS prehospital setting. Although statistical significance was not observed in this exploratory study, comparison with a historical control period suggests a potential association of esmolol with higher ROSC rates. Future work at a larger scale is needed to determine the effect of prehospital esmolol for RVF on neurologically intact hospital discharge. Esmolol in the management of prehospital refractory ventricular fibrillation: a systematic review and meta-analysis Recurrent ventricular fibrillation during advanced life support care of patients with prehospital cardiac arrest Electrical storm: definitions, clinical importance, and treatment. urrO pin Cardiol The evaluation and management of electrical storm Heart Disease and Stroke Statistics-2019 Up-date: a Report From the American Heart Association Incidence and outcomes of out-of-hospital cardiac arrest with shock-resistant ventricular fibrillation: data from a large population-based cohort Immediate coronary angiography in survivors of out-of-hospital cardiac arrest Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation Refractory ventricular fibrillation treated with esmolol Short-acting betaadrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation Effect and mechanism of esmolol given during cardiopulmonary resuscitation in a porcine ventricular fibrillation model Beta1-adrenergic blockade during cardiopulmonary resuscitation improves survival Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, openlabel, randomised controlled trial Double sequential external defibrillation for refractory ventricular fibrillation: the DOSE VF pilot randomized controlled trial Effectiveness of prehospital dual sequential defibrillation for refractory ventricular fibrillation and ventricular tachycardia cardiac arrest PARAMEDIC2 Collaborators. A randomized trial of epinephrine in out-of-hospital cardiac arrest Oxygen uptake of the nonworking left ventricle Myocardial oxygen consumption and coronary blood flow during potassium-induced cardiac arrest and during ventricular fibrillation The authors have no conflict of interest to disclose.